CN1103404A - 识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物 - Google Patents

识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物 Download PDF

Info

Publication number: CN1103404A
Authority: CN; China
Prior art keywords: monoclonal antibody; egf; cell; antibody; produce
Prior art date: 1993-03-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN 94104094

Other languages

English (en)

Chinese (zh)

Inventor

A·F·奥道尼兹

C·M·梅特奥

A·E·M·亚伯拉罕

P·R·M·佩雷兹

B·R·T·布雷弗

R·P·罗德里戈兹

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Centro de Immunologia Molecular

Original Assignee

Centro de Immunologia Molecular

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-01

Filing date

1994-02-26

Publication date

1995-06-07

1994-02-26 Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular

1995-06-07 Publication of CN1103404A publication Critical patent/CN1103404A/zh

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 64
239000000203 mixture Substances 0.000 title claims description 21
102000001301 EGF receptor Human genes 0.000 title abstract description 8
108060006698 EGF receptor Proteins 0.000 title abstract description 8
230000000295 complement effect Effects 0.000 claims abstract description 28
230000001404 mediated effect Effects 0.000 claims abstract description 22
210000002826 placenta Anatomy 0.000 claims abstract description 20
230000012010 growth Effects 0.000 claims abstract description 17
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims abstract description 12
230000035755 proliferation Effects 0.000 claims abstract description 12
210000004027 cell Anatomy 0.000 claims description 123
210000004408 hybridoma Anatomy 0.000 claims description 47
238000012216 screening Methods 0.000 claims description 32
206010028980 Neoplasm Diseases 0.000 claims description 30
210000004881 tumor cell Anatomy 0.000 claims description 26
238000011282 treatment Methods 0.000 claims description 25
150000003408 sphingolipids Chemical class 0.000 claims description 23
231100000135 cytotoxicity Toxicity 0.000 claims description 21
230000005764 inhibitory process Effects 0.000 claims description 21
230000003013 cytotoxicity Effects 0.000 claims description 20
230000004663 cell proliferation Effects 0.000 claims description 15
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 14
125000003047 N-acetyl group Chemical group 0.000 claims description 13
201000005202 lung cancer Diseases 0.000 claims description 13
208000020816 lung neoplasm Diseases 0.000 claims description 13
201000011510 cancer Diseases 0.000 claims description 12
230000000890 antigenic effect Effects 0.000 claims description 11
238000012360 testing method Methods 0.000 claims description 11
206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
201000000050 myeloid neoplasm Diseases 0.000 claims description 8
108060003951 Immunoglobulin Proteins 0.000 claims description 7
239000012634 fragment Substances 0.000 claims description 7
102000018358 immunoglobulin Human genes 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
230000036039 immunity Effects 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 4
238000004321 preservation Methods 0.000 claims description 4
230000003302 anti-idiotype Effects 0.000 claims description 3
230000001419 dependent effect Effects 0.000 claims description 3
230000009977 dual effect Effects 0.000 claims description 3
239000011159 matrix material Substances 0.000 claims description 3
241001465754 Metazoa Species 0.000 claims 5
238000010171 animal model Methods 0.000 claims 3
241001597008 Nomeidae Species 0.000 claims 1
241000283984 Rodentia Species 0.000 claims 1
210000001124 body fluid Anatomy 0.000 claims 1
239000010839 body fluid Substances 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
238000013467 fragmentation Methods 0.000 claims 1
238000006062 fragmentation reaction Methods 0.000 claims 1
238000001727 in vivo Methods 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
238000011321 prophylaxis Methods 0.000 claims 1
238000000926 separation method Methods 0.000 claims 1
102000005962 receptors Human genes 0.000 abstract description 7
108020003175 receptors Proteins 0.000 abstract description 7
230000001472 cytotoxic effect Effects 0.000 abstract description 6
150000002270 gangliosides Chemical class 0.000 abstract description 2
230000002401 inhibitory effect Effects 0.000 abstract description 2
230000002195 synergetic effect Effects 0.000 abstract 1
230000001173 tumoral effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 description 31
210000001519 tissue Anatomy 0.000 description 21
239000006228 supernatant Substances 0.000 description 20
239000000427 antigen Substances 0.000 description 16
102000036639 antigens Human genes 0.000 description 16
108091007433 antigens Proteins 0.000 description 16
238000002360 preparation method Methods 0.000 description 14
230000004614 tumor growth Effects 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
239000007788 liquid Substances 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 10
239000012636 effector Substances 0.000 description 10
238000011160 research Methods 0.000 description 10
238000002474 experimental method Methods 0.000 description 8
210000004988 splenocyte Anatomy 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
239000012530 fluid Substances 0.000 description 7
206010006187 Breast cancer Diseases 0.000 description 6
208000026310 Breast neoplasm Diseases 0.000 description 6
239000003814 drug Substances 0.000 description 6
230000004927 fusion Effects 0.000 description 6
210000004907 gland Anatomy 0.000 description 6
239000001488 sodium phosphate Substances 0.000 description 6
229910000162 sodium phosphate Inorganic materials 0.000 description 6
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
206010003445 Ascites Diseases 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
231100000433 cytotoxic Toxicity 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
230000000452 restraining effect Effects 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
230000003211 malignant effect Effects 0.000 description 4
210000001589 microsome Anatomy 0.000 description 4
-1 polyoxyethylene Polymers 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
102000013275 Somatomedins Human genes 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
241000173347 Tonsilla Species 0.000 description 3
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 3
239000003513 alkali Substances 0.000 description 3
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
230000003305 autocrine Effects 0.000 description 3
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
210000002615 epidermis Anatomy 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000005075 mammary gland Anatomy 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
210000005152 placental membrane Anatomy 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000002356 single layer Substances 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
210000001550 testis Anatomy 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
206010053717 Fibrous histiocytoma Diseases 0.000 description 2
230000005526 G1 to G0 transition Effects 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
206010062767 Hypophysitis Diseases 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
208000005890 Neuroma Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
230000035578 autophosphorylation Effects 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
244000309466 calf Species 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
210000001638 cerebellum Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
230000024835 cytogamy Effects 0.000 description 2
238000013016 damping Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000009422 growth inhibiting effect Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
210000003677 hemocyte Anatomy 0.000 description 2
229940000351 hemocyte Drugs 0.000 description 2
201000000284 histiocytoma Diseases 0.000 description 2
210000004754 hybrid cell Anatomy 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
108020004084 membrane receptors Proteins 0.000 description 2
206010027191 meningioma Diseases 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
208000029974 neurofibrosarcoma Diseases 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
210000001913 submandibular gland Anatomy 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
229960005508 8-azaguanine Drugs 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
241000521299 Deinocerites cancer Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
206010025538 Malignant ascites Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
101150034459 Parpbp gene Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000220317 Rosa Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000003450 affinity purification method Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
201000010983 breast ductal carcinoma Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
238000005530 etching Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000011177 media preparation Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000012882 sequential analysis Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
230000003335 steric effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000012747 synergistic agent Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Images

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CN 94104094 1993-03-01 1994-02-26 识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物 Pending CN1103404A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CA17/93		1993-03-01
CU1993017		1993-03-01

Publications (1)

Publication Number	Publication Date
CN1103404A true CN1103404A (zh)	1995-06-07

Family

ID=5459200

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN 94104094 Pending CN1103404A (zh)	1993-03-01	1994-02-26	识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物

Country Status (2)

Country	Link
CN (1)	CN1103404A (fr)
CA (1)	CA2116753C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103998098A (zh) *	2011-12-27	2014-08-20	分子免疫中心	用于治疗表达EGFR和N-羟乙酰GM3神经节苷脂(NeuGcGM3)的肿瘤的药物组合物

1994
- 1994-02-26 CN CN 94104094 patent/CN1103404A/zh active Pending
- 1994-03-01 CA CA 2116753 patent/CA2116753C/fr not_active Expired - Lifetime

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103998098A (zh) *	2011-12-27	2014-08-20	分子免疫中心	用于治疗表达EGFR和N-羟乙酰GM3神经节苷脂(NeuGcGM3)的肿瘤的药物组合物
CN103998098B (zh) *	2011-12-27	2017-08-04	分子免疫中心	用于治疗表达EGFR和N‑羟乙酰GM3神经节苷脂(NeuGcGM3)的肿瘤的药物组合物

Also Published As

Publication number	Publication date
CA2116753C (fr)	2001-09-04
CA2116753A1 (fr)	1994-09-02

Legal Events

Date	Code	Title
1995-06-07	C06	Publication
1995-06-07	PB01	Publication
1996-05-29	C10	Entry into substantive examination
1996-05-29	SE01	Entry into force of request for substantive examination
2002-01-23	C12	Rejection of a patent application after its publication
2002-01-23	RJ01	Rejection of invention patent application after publication

Publication	Publication Date	Title
EP3882276A1 (fr)	2021-09-22	Anticorps bispécifique, son procédé de préparation et son utilisation
UA74330C2 (uk)	2005-12-15	СПОСОБИ ВИКОРИСТАННЯ РОЗЧИННОГО РЕЦЕПТОРА BR43x2
JP2017502048A (ja)	2017-01-19	小細胞肺癌に対する標的療法
CN1165539A (zh)	1997-11-19	肽及蛋白质的修饰
JP2022518519A (ja)	2022-03-15	新規二重特異性抗体分子及びｐｄ－ｌ１とｌａｇ－３と同時に結合する二重特異性抗体
JP2024506758A (ja)	2024-02-14	改変された幹細胞組成物およびその使用方法
JPH10501411A (ja)	1998-02-10	細胞周期非依存性グリオーマ細胞表面抗原特異的ヒト・モノクロナール抗体
CN1187373C (zh)	2005-02-02	人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
CN1268954A (zh)	2000-10-04	治疗与有害鸟嘌呤核苷酸交换因子活性相关的异常细胞生长的方法和组合物
CN1103404A (zh)	1995-06-07	识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物
CN1420128A (zh)	2003-05-28	人源化抗her2单克隆抗体及其制法和药物组合物
CN1946425A (zh)	2007-04-11	B细胞疾病的靶
CN1826137A (zh)	2006-08-30	α1β1整联蛋白的可诱导的配体和用途
CN1827647A (zh)	2006-09-06	重组抗egfr单克隆抗体
JP4413611B2 (ja)	2010-02-10	Ｇ−ｃｓｆ遺伝子におけるエキソン３の領域の欠失について測定することを特徴とするガンの診断方法
US20090081221A1 (en)	2009-03-26	Method for suppressing cancer cell metastasis and pharmaceutical composition for use in the method
CN1621413A (zh)	2005-06-01	一种c－型凝集素及其编码基因
CN1190491C (zh)	2005-02-23	Prv－1基因及其应用
CN1171903C (zh)	2004-10-20	小麦高分子量谷蛋白亚基单克隆抗体及其杂交瘤细胞系
Kimura et al.	1995	Leukemic transformation of primary myelofibrosis: immunophenotype, genotype and growth characteristics of blast cells
CN1844149A (zh)	2006-10-11	抗人4－1bbl单克隆抗体制备及其应用
JP2007106716A (ja)	2007-04-26	Ｉｓｇ１５タンパク質と特異的に反応するモノクローナル抗体及びそれを産生するハイブリドーマ並びに癌およびウイルス感染の検出方法
CN1844145A (zh)	2006-10-11	抗人ox40l单克隆抗体的制备及其应用
CN1285613C (zh)	2006-11-22	抗肿瘤大鼠轻链单域抗体－力达霉素强化融合蛋白vl－ldp－ae
CN1297922A (zh)	2001-06-06	一种多肽－人钙结合s100蛋白21和编码该多肽的多核苷酸